ARNA Arena Pharmaceuticals Inc

Price (delayed)

$80.70

Market cap

$4.69B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.09

Enterprise value

$4.28B

Sector: Healthcare
Industry: Biotechnology

Highlights

ARNA's debt is down by 7% YoY and by 2.1% from the previous quarter
The quick ratio has declined by 20% since the previous quarter but it has increased by 5% year-on-year
ARNA's equity is down by 6% QoQ but it is up by 2.1% YoY
Arena Pharmaceuticals's net income has plunged by 167% YoY and by 7% from the previous quarter
The EPS has shrunk by 163% YoY and by 3.4% QoQ

Key stats

What are the main financial stats of ARNA
Market
Shares outstanding
58.16M
Market cap
$4.69B
Enterprise value
$4.28B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.98
Price to sales (P/S)
1,419.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,303.38
Earnings
Revenue
$3.28M
EBIT
-$366.33M
EBITDA
-$362.55M
Free cash flow
-$310.71M
Per share
EPS
-$7.09
Free cash flow per share
-$5.38
Book value per share
$20.29
Revenue per share
$0.06
TBVPS
$22.08
Balance sheet
Total assets
$1.28B
Total liabilities
$105.62M
Debt
$46.62M
Equity
$1.17B
Working capital
$1.15B
Liquidity
Debt to equity
0.04
Current ratio
23.17
Quick ratio
22.5
Net debt/EBITDA
1.14
Margins
EBITDA margin
-11,039.9%
Gross margin
100%
Net margin
-11,293.7%
Operating margin
-11,729.9%
Efficiency
Return on assets
-30.4%
Return on equity
-33.2%
Return on invested capital
-42.5%
Return on capital employed
-29.9%
Return on sales
-11,155.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARNA stock price

How has the Arena Pharmaceuticals stock price performed over time
Intraday
0.25%
1 week
4.82%
1 month
11.46%
1 year
72.92%
YTD
5.04%
QTD
5.04%

Financial performance

How have Arena Pharmaceuticals's revenue and profit performed over time
Revenue
$3.28M
Gross profit
$3.28M
Operating income
-$385.21M
Net income
-$370.88M
Gross margin
100%
Net margin
-11,293.7%
The operating income has dropped by 172% year-on-year and by 5% since the previous quarter
Arena Pharmaceuticals's net income has plunged by 167% YoY and by 7% from the previous quarter
The gross profit has plunged by 100% YoY and by 29% from the previous quarter
The revenue has dropped by 100% year-on-year and by 29% since the previous quarter

Growth

What is Arena Pharmaceuticals's growth rate over time

Valuation

What is Arena Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.98
P/S
1,419.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,303.38
The EPS has shrunk by 163% YoY and by 3.4% QoQ
The P/B is 69% less than the 5-year quarterly average of 12.7 but 53% more than the last 4 quarters average of 2.6
ARNA's equity is down by 6% QoQ but it is up by 2.1% YoY
ARNA's price to sales (P/S) is 135% more than its last 4 quarters average of 603.2
The revenue has dropped by 100% year-on-year and by 29% since the previous quarter

Efficiency

How efficient is Arena Pharmaceuticals business performance
ARNA's return on invested capital has dropped by 164% year-on-year and by 15% since the previous quarter
ARNA's ROE has plunged by 163% YoY and by 7% from the previous quarter
ARNA's ROA has dropped by 162% year-on-year and by 6% since the previous quarter
The ROS has shrunk by 51% QoQ

Dividends

What is ARNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARNA.

Financial health

How did Arena Pharmaceuticals financials performed over time
The quick ratio has declined by 20% since the previous quarter but it has increased by 5% year-on-year
ARNA's current ratio is down by 19% from the previous quarter but it is up by 6% YoY
ARNA's debt is 96% less than its equity
ARNA's debt is down by 7% YoY and by 2.1% from the previous quarter
ARNA's equity is down by 6% QoQ but it is up by 2.1% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.